SCHEMBL853629

SCHEMBL853629

Nc1ccc(C(=O)NCCO)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.61
MAPT P10636 1/20 0.61
HIF1A Q16665 1/20 0.61
SLC22A6 Q4U2R8 1/20 0.61
SLC22A8 Q8TCC7 1/20 0.61
LMNA P02545 3/20 0.60
TSHR P16473 2/20 0.60
ALDH1A1 P00352 2/20 0.60
SLC22A2 O15244 1/20 0.60
SLC22A1 O15245 1/20 0.60
ACHE P22303 1/20 0.60
MAPK1 P28482 1/20 0.60
CYP2C19 P33261 1/20 0.60
BLM P54132 2/20 0.58
PMP22 Q01453 2/20 0.58
CA12 O43570 1/20 0.58
CA1 P00915 1/20 0.58
CA2 P00918 1/20 0.58
CA9 Q16790 1/20 0.58
CA14 Q9ULX7 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21360586 0.90 KDM4E (0.51) KDM4EMAPTHIF1ASLC22A6SLC22A8
SCHEMBL9344489 0.90 KDM4E (0.68) KDM4EMAPTHIF1ASLC22A6SLC22A8
SCHEMBL620074 0.89 POLB (0.66) KDM4ELMNATSHRALDH1A1MAPK1
SCHEMBL3000922 0.89 POLB (0.58) KDM4EMAPTHIF1ASLC22A6SLC22A8
SCHEMBL18874371 0.87 LMNA (0.49) KDM4EMAPTHIF1ASLC22A6SLC22A8
SCHEMBL3399829 0.87 LMNA (0.64) KDM4EMAPTHIF1ASLC22A6SLC22A8
SCHEMBL11230329 0.86 KDM4E (0.63) KDM4EMAPTHIF1ASLC22A6SLC22A8
SCHEMBL12515200 0.86 KDM4E (0.63) KDM4EMAPTHIF1ASLC22A6SLC22A8
SCHEMBL9419699 0.84 MAPK1 (0.65) KDM4EMAPTHIF1ASLC22A6SLC22A8
SCHEMBL11619588 0.84 TSHR (0.70) KDM4EMAPTHIF1ASLC22A6SLC22A8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025085689-A1 EXTRACELLULAR SMALL MOLECULE ACTIVATORS TARGETING BESTROPHIN CHANNELS FOR DISEASE TREATMENT THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2025-04-24 WO claimed
CN-116874266-B Detachable acoustic insulation board and manufacturing method thereof 宝都国际新材料有限公司 2023-12-12 CN claimed
CN-116874266-A Detachable acoustic insulation board and manufacturing method thereof 宝都国际新材料有限公司 2023-10-13 CN claimed
CN-116496452-A Low-sensitivity super-early-strength polycarboxylate superplasticizer and preparation method thereof 厦门路桥翔通建材科技有限公司 2023-07-28 CN claimed
US-20100190773-A1 Anti-Cytokine Heterocyclic Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-07-29 US claimed
EP-2188289-A2 (7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-PIPERAZINES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATION Lexicon Pharmaceuticals, Inc. (US) 2010-05-26 EP claimed
WO-2009021169-A2 (7H-PYRR0L0 [2, 3-D] PYRIMIDIN-4-YL) -PIPERAZINES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATION LEXICON PHARMACEUTICALS, INC. (US) 2009-02-12 WO claimed
US-20060276496-A1 Anti-Cytokine Heterocyclic Compounds BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-12-07 US claimed
WO-2025085689-A1 EXTRACELLULAR SMALL MOLECULE ACTIVATORS TARGETING BESTROPHIN CHANNELS FOR DISEASE TREATMENT THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2025-04-24 WO disclosed
EP-4306532-A2 CHEMICAL CLEAVAGE AND DEPROTECTION Illumina, Inc. (US) 2024-01-17 EP disclosed
CN-116874266-B Detachable acoustic insulation board and manufacturing method thereof 宝都国际新材料有限公司 2023-12-12 CN disclosed
CN-116874266-B Detachable acoustic insulation board and manufacturing method thereof 宝都国际新材料有限公司 2023-12-12 CN disclosed
WO-2023220440-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-11-16 WO disclosed
EP-3794012-B1 COMPOSITIONS AND METHODS FOR CHEMICAL CLEAVAGE AND DEPROTECTION OF SURFACE-BOUND OLIGONUCLEOTIDES ILLUMINA INC (US) 2023-10-18 EP disclosed
US-5405851-A Administering benzoquinazoline thymidylate synthase inhibitors BURROUGHS WELLCOME CO. (US) 1995-04-11 US disclosed
US-5298036-A Polyamide fibers CIBA-GEIGY CORPORATION (US) 1994-03-29 US disclosed
EP-0535034-A1 PHARMACEUTICALLY ACTIVE BENZOQUINAZOLINE COMPOUNDS THE WELLCOME FOUNDATION LIMITED (GB) 1993-04-07 EP disclosed
WO-1991019700-A1 PHARMACEUTICALLY ACTIVE BENZOQUINAZOLINE COMPOUNDS THE WELLCOME FOUNDATION LIMITED (GB) 1991-12-26 WO disclosed
US-4642322-A Stabilization of chlorine-containing thermoplastics with nitrogen-containing organic compounds CIBA-GEIGY CORPORATION (US) 1987-02-10 US disclosed
US-4412992-A 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith BIOREX LABORATORIES LIMITED (GB) 1983-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276496-A1 Anti-Cytokine Heterocyclic Compounds MAPKAPK2, MAP4K2, MAP3K2 KDM4E 2943/4885MAPT 1938/4885HIF1A 2401/4885
US-20100190773-A1 Anti-Cytokine Heterocyclic Compounds MAPKAPK2, MAP4K2, MAP3K2 KDM4E 2943/4885MAPT 1938/4885HIF1A 2401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.